A Spectrum of PCSK9 Alleles Contributes to Plasma Levels of Low-Density Lipoprotein Cholesterol  by Kotowski, Ingrid K. et al.
410 The American Journal of Human Genetics Volume 78 March 2006 www.ajhg.org
A Spectrum of PCSK9 Alleles Contributes to Plasma Levels
of Low-Density Lipoprotein Cholesterol
Ingrid K. Kotowski,1,4,5 Alexander Pertsemlidis,1,3 Amy Luke,7 Richard S. Cooper,2,7
Gloria L. Vega,2,6 Jonathan C. Cohen,1,2,3,6 and Helen H. Hobbs1,2,3,4,5
1McDermott Center for Human Growth and Development, 2Donald W. Reynolds Cardiovascular Clinical Research Center, Departments
of 3Internal Medicine and 4Molecular Genetics, 5Howard Hughes Medical Institute, and 6Center for Human Nutrition, University of Texas
Southwestern Medical Center, Dallas; and 7Department of Preventive Medicine and Epidemiology, Loyola University Medical Center,
Maywood, IL
Selected missense mutations in the proprotein convertase subtilisin/kexin type 9 serine protease gene (PCSK9) cause
autosomal dominant hypercholesterolemia, whereas nonsense mutations in the same gene are associated with low
plasma levels of low-density lipoprotein cholesterol (LDL-C). Here, DNA sequencing and chip-based oligonucleotide
hybridization were used to determine whether other sequence variations in PCSK9 contribute to differences in LDL-
C levels. The coding regions of PCSK9 were sequenced in the blacks and whites from the Dallas Heart Study
( ) who had the lowest (!5th percentile) and highest (195th percentile) plasma levels of LDL-C. Of thenp 3,543
17 missense variants identiﬁed, 3 (R46L, L253F, and A443T) were signiﬁcantly and reproducibly associated with
lower plasma levels of LDL-C (reductions ranging from 3.5% to 30%). None of the low–LDL-C variants were
associated with increased hepatic triglyceride content, as measured by proton magnetic resonance spectroscopy.
This ﬁnding is most consistent with the reduction in LDL-C being caused primarily by accelerating LDL clearance,
rather than by reduced lipoprotein production. Association studies with 93 noncoding single-nucleotide polymor-
phisms (SNPs) at the PCSK9 locus identiﬁed 3 SNPs associated with modest differences in plasma LDL-C levels.
Thus, a spectrum of sequence variations ranging in frequency (from 0.2% to 34%) and magnitude of effect (from
a 3% increase to a 49% decrease) contribute to interindividual differences in LDL-C levels. These ﬁndings reveal
that PCSK9 activity is a major determinant of plasma levels of LDL-C in humans andmake it an attractive therapeutic
target for LDL-C lowering.
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Elevated levels of plasma low-density lipoprotein cho-
lesterol (LDL-C) are a major risk factor for the devel-
opment and progression of atherosclerosis, which can
result in coronary artery disease and stroke. Plasma lev-
els of LDL-C vary over a threefold range in the popu-
lation, and both family and twin studies have consis-
tently shown that ∼50% of the variation is genetic in
etiology (Rao et al. 1982; Heller et al. 1993). Although
multiple genetic defects have been identiﬁed that cause
rare Mendelian forms of severe hypercholesterolemia or
hypocholesterolemia, the sequence variations in the ge-
nome accounting for most of the variation in plasma
cholesterol levels in the general population have not been
determined.
LDLs are formed in the circulation as a metabolic
product of very-low-density lipoprotein (VLDL) and
are cleared from the blood by LDL receptor (LDLR)–
mediated endocytosis in the liver. Disruption of the
LDLR pathway is associated with severe hypercholes-
terolemia. Inactivatingmutations inLDLR (MIM606945)
or in the LDLR-binding region of apolipoprotein B-100
(apoB-100) cause severe autosomal dominant hyper-
cholesterolemia (MIM 144010) (Innerarity et al. 1990;
Goldstein et al. 2001), and mutations in ARH, an adap-
tor protein required for LDLR endocytosis, cause au-
tosomal recessive hypercholesterolemia (MIM 603813)
(Garcia et al. 2001). No common sequence variations
in the genes defective in Mendelian forms of hypercho-
lesterolemia (or hypocholesterolemia) have been con-
vincingly and reproducibly shown to contribute signif-
icantly to interindividual differences in plasma levels of
cholesterol in the general population.
Recently, selected missense mutations in PCSK9 were
found to cause severe hypercholesterolemia (Abifadel et
al. 2003; Leren 2004; Timms et al. 2004). PCSK9 en-
codes a 692-aa glycoprotein that is a member of the
subtilisin/kexin type 9 serine protease subfamily of pro-
protein convertases. PCSK9 contains a signal sequence
and prodomain at its N-terminus, followed by a catalytic
domain and cysteine-rich carboxy-terminal domain (ﬁg.
1) (Naureckiene et al. 2003; Seidah et al. 2003; Benjan-
net et al. 2004). PCSK9 undergoes autocatalytic cleav-
age in the endoplasmic reticulum, releasing the amino-
terminal prodomain (Naureckiene et al. 2003; Seidah et
al. 2003; Benjannet et al. 2004). The prodomain remains
associated with the processed form of PCSK9 as it tran-
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Figure 1 Nonsynonymous sequence variations in PCSK9 iden-
tiﬁed in the DHS subjects. PCSK9 contains a 30-aa signal peptide (SP)
followed by a prodomain (Pro). The proconvertase undergoes auto-
catalytic processing to release the 14-kDa prodomain peptide from the
amino-terminus (Benjannet et al. 2004). The catalytic domain, which
contains the catalytic triad of aspartate (D), histidine (H), and serine
(S) as well as a highly conserved asparagine (N), is followed by a
carboxy-terminal domain, which contains an N-linked glycosylation
site. The sites of the nonsynonymous mutations identiﬁed in only the
high-LDL subjects, in only the low-LDL subjects, or in both groups
of the DHS sample are shown. The mutations that are signiﬁcantly
associated with an increase (yellow) or decrease (green) in plasma
LDL-C levels in the DHS samples are indicated. Mutations identiﬁed
initially by Abifadel et al. (2003), Cohen et al. (2005), or Benjannet
et al. (2004) are indicated by a superscript A, B, or C, respectively.
sits through the secretory pathway (Seidah et al. 2003).
PCSK9 is expressed most abundantly in the liver, kidney,
and small intestine (Seidah et al. 2003). Hepatic levels
of PCSK9mRNA change inversely with cholesterol feed-
ing in mice (Maxwell et al. 2003) and are elevated in
mice overexpressing constitutively active forms of the
cholesterol regulatory transcription factors SREBP-1a
and SREBP-2 (Horton et al. 2003).
The physiological substrate(s) of PCSK9 is not known,
but high-level expression of recombinant PCSK9 in the
livers of mice results in a pronounced reduction in LDLR
protein level and hypercholesterolemia without any as-
sociated changes in LDLR mRNA level (Benjannet et
al. 2004; Maxwell and Breslow 2004; Park et al. 2004).
These data suggest that missense mutations in PCSK9
cause hypercholesterolemia by a gain-of-function mech-
anism and promote the degradation of LDLRs in he-
patocytes (Benjannet et al. 2004; Maxwell and Breslow
2004; Park et al. 2004). An alternative hypothesis is that
PCSK9 affects plasma LDL-C levels by altering the rate
of secretion of apoB-100 in an LDLR-independent man-
ner (Benjannet et al. 2004; Ouguerram et al. 2004; Sun
et al. 2005). Metabolic studies measuring VLDL–apoB-
100 synthesis in two individuals with a missense mu-
tation in PCSK9 found a signiﬁcant increase in VLDL
production (Ouguerram et al. 2004), whereas conﬂicting
results have been obtained with regard to the effect of
PCSK9 expression on apoB-100 synthesis in the livers
of mice or in cultured hepatocytes isolated from mice
expressing recombinant PCSK9 (Park et al. 2004; La-
lanne et al. 2005). Additional studies will be required
to determine whether increased synthesis of apoB-con-
taining lipoproteins by the liver contributes to the hy-
percholesterolemia associated with missense mutations
in PCSK9.
Mutations in PCSK9 result not only in severe hyper-
cholesterolemia but also in hypocholesterolemia (Cohen
et al. 2005). Two different nonsense mutations inPCSK9
are associated with a 40% reduction in mean plasma
levels of LDL-C (Cohen et al. 2005), presumably because
of a loss of PCSK9 function resulting in elevated hepatic
LDLR activity. Mice lacking PCSK9 have markedly in-
creased hepatic LDLR levels (Rashid et al. 2005). Thus,
selected missense mutations in PCSK9 produce hyper-
cholesterolemia due to a gain of function, resulting in
reduced hepatic levels of LDLR, whereas inactivating
mutations in the same gene cause hypocholesterolemia
due to a loss of function, resulting in an increased level
of LDLR in the liver.
Since mutations in PCSK9 can cause severe domi-
nant hypercholesterolemia (Abifadel et al. 2003; Leren
2004; Timms et al. 2004) as well as signiﬁcantly reduced
plasma levels of LDL-C (Cohen et al. 2005), other in-
vestigators have queried whether other more common
sequence variations in PCSK9 contribute to variations
in plasma levels of LDL-C. Shioji et al. (2004) identiﬁed
two SNPs, and Chen et al. (2005) identiﬁed a haplotype
associated with differences in plasma LDL-C level, but
no systematic examination of the relationship between
sequence variations in PCSK9 and plasma levels of LDL-
C has been reported.
The aim of the present study was to characterize the
spectrum of sequence variations in PCSK9 and to in-
vestigate the contributions of these variations to differ-
ences in plasma levels of LDL-C in the general popu-
lation. In addition, we investigated whether functional
sequence variations in PCSK9 associated with low
plasma levels of LDL-C are also associated with in-
creased hepatic triglyceride content (HTGC), as would
be expected if defects in PCSK9 cause reduced produc-
tion of apoB-containing lipoproteins by the liver.
Subjects and Methods
Subjects
Informed consent, blood samples, and clinical evaluations
were obtained for all participating subjects by institutional
review board–approved protocols. The study population in-
cluded all participants in the Dallas Heart Study (DHS) from
whom fasting venous blood samples were obtained (np
). The DHS sample is a multiethnic, probability-based3,543
sample of Dallas County, weighted to include 50% blacks, in
which ethnicity was self-assigned in accordance with United
States census categories (Victor et al. 2004). In the present
study, “blacks” and “whites” refer to individuals who self-
identiﬁed as non-Hispanic black and non-Hispanic white, re-
spectively. The blood samples were maintained at 4C until
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Table 1
Nonsynonymous Sequence Variations in PCSK9 Identiﬁed in Blacks and Whites
in the DHS Sample Who Had Plasma LDL-C Levels !5th or 195th Percentile
SUBJECTS AND
NUCLEOTIDE SUBSTITUTION
AMINO ACID
SUBSTITUTION
MINOR-ALLELE FREQUENCYa IN DHS
(%)
Blacks
( )np 1,822
Whites
( )np 1,045
Hispanics
( )np 601
Low-LDL subjects only:
c.169GrA E57K .33 … …
c.426CrG Y142Xb .19 … …
c.757CrT L253F .25 … .084
c.1171CrA H391N .41 … .083
c.1660CrG Q554E .30 … .084
c.2037CrA C679Xb .72 .048 .084
Total 2.2 .048 .33
High-LDL subjects only:
c.709CrT R237Wb .028 .24 .084
c.1251CrA H417Q .30 .048 …
c.1405CrT R469W .75 .049 .084
c.1445ArG E482G .11 … …
c.1545TrG F515L .028 … …
c.1658ArG H553R 1.3 … …
Total 2.5 .33 .17
Both low- and high-LDL subjects:
c.137GrT R46Lb .28 1.6 .75
c.158CrT A53Vb 1.8 13 4.6
c.1274ArG N425S 1.9 … .17
c.1327GrA A443T 9.4 .048 1.3
c.1420ArG I474Vb 22 18 9.7
c.1856ArC Q619P 1.5 … …
c.2009ArG E670Gb 26 3.6 4.2
Total 62 35 20
a Minor-allele frequency for each sequence variation was calculated within each ethnic group
on the basis of the total number of genotypes for that sequence variation. Combined minor-allele
frequency was calculated on the basis of the total number of subjects.
b Reported elsewhere (Abifadel et al. 2003; Benjannet et al. 2004; Leren 2004; Shioji et al.
2004; Timms et al. 2004; Cohen et al. 2005).
the plasma and serum were separated, aliquoted, and stored
at 80C. Genomic DNA was isolated from the leukocytes
with Pure Gene (Gentra Systems). Signiﬁcant associations were
replicated in a sample of blacks fromMaywood, Cook County,
Illinois (Cohen et al. 2005).
Measurement of Plasma LDL-C Levels
and Determination of HTGC
Plasma LDL-C concentrations were determined using com-
mercial enzymatic reagents. HTGC was determined by proton
nuclear magnetic resonance spectroscopy as described else-
where (Browning et al. 2004; Szczepaniak et al. 2004). Hepatic
steatosis was deﬁned as HTGC 15.5% (Browning et al. 2004).
PCR and DNA Sequencing
Within each ethnic- and sex-speciﬁc group, plasma LDL-C
levels were adjusted for the effects of age by linear regression
and for the effects of lipid-lowering medications by the as-
sumption of a 25% decrease in plasma LDL-C level. For se-
quencing, we selected the 5% of individuals with the highest
and lowest adjusted plasma LDL-C levels in each ethnic- and
sex-speciﬁc group whose fasting plasma levels of triglycerides
were !250 mg/dl. The 5th and 95th percentiles, respectively,
of the adjusted plasma LDL-C levels were 49 mg/dl and 177
mg/dl for black men ( ), 56 mg/dl and 172 mg/dl fornp 770
black women ( ), 61 mg/dl and 171 mg/dl for whitenp 1,051
men ( ), and 57 mg/dl and 168 mg/dl for white womennp 499
( ).np 544
The exons and ﬂanking intronic sequences of PCSK9 were
ampliﬁed by PCR and treated with recombinant exonuclease
I and shrimp alkaline phosphatase (Exo-Sap [USB]). Both
strands of each product were sequenced on an ABI 3730 au-
tomated sequencer with BigDye terminator cycle sequencing
reagents (Applied Biosystems). The sequences of the oligo-
nucleotides used for sequencing are available on request.
Assay of Mutations
Speciﬁc 5′-nucleotidase assays for all nonsynonymous se-
quence variations identiﬁed by sequencing in the present study
were developed using the TaqMan system (Applied Biosys-
tems). The assays were performed on an HT7900 Real-Time
PCR system with probes and reagents purchased from Applied
Biosystems. All other SNPs were genotyped by PCR-based am-
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Figure 2 Plasma LDL-C levels in whites in the DHS sample.
A, Subjects were genotyped by speciﬁc 5′-nucleotidase assay. Themean
age- and sex-adjusted plasma LDL-C level of all whites in the DHS
sample is indicated by the solid horizontal line (1 SD is indicated
by the dotted lines). Each point in the plot represents the LDL-C level
of an individual who is heterozygous or homozygous for the rare allele
(/) of the indicated sequence variation. Horizontal bars, Mean
plasma LDL-C levels for each sequence variant (omitted if ; seen ! 6
the “Subjects and Methods” section). The green-shaded bar indicates
a signiﬁcantly lower plasma LDL-C level ( , by one-way anal-4P ! 10
ysis of variance). B, Mean ( SEM) of the plasma LDL-C levels for
the R46L variation. R46L is signiﬁcantly associated with decreased
plasma LDL-C level in the DHS whites (left set of bars), white men
(center set of bars), and white women (right set of bars). The number
of subjects in each group is given above the bars. ** , ***P ! .01 P !
; by two-sided t test.410
pliﬁcation of genomic DNA, followed by hybridization to
high-density oligonucleotide arrays (Perlegen Sciences).
Statistical Analysis
We used the statistical software package R for all statistical
analyses (The R Development Core Team 2004; The R Project
for Statistical Computing). The observed genotype frequencies
were tested for deviation from Hardy-Weinberg equilibrium
by using x2 tests. Tests for association were performed in the
DHS sample and were then validated by replication in the
Cook County sample. Individuals taking lipid-lowering drugs
were excluded from all tests for association with plasma LDL-
C levels. Lipoprotein levels were adjusted for age and sex by
linear regression and were tested for association with each
sequence variant by using one-way analysis of variance, to
compare the mean values of the three genotype groups. Ge-
notypes represented by fewer than six individuals were omitted
from the analysis. Blacks and whites in the DHS sample were
analyzed separately. Sequence variants found to be signiﬁcantly
associated with plasma LDL-C levels at a nominal signiﬁcance
threshold of 0.05 in the DHS blacks were tested for association
in the Cook County sample by using unpaired t tests. Since
the direction of effect was already established in the DHS
sample, associations in the Cook County sample were exam-
ined using one-sided tests. Sequence variants that achieved
a nominal signiﬁcance threshold of 0.05 in the DHS and
Cook County samples and that showed the same direction of
effect in the two samples were considered to be statistically
signiﬁcant.
Haplotype Analysis of PCSK9
We estimated haplotype blocks in each ethnic group, using
the expectation-maximization algorithm (as implemented in
Haploview [Barrett et al. 2005]) and the Gabriel et al. (2002)
deﬁnition of haplotype blocks, and we calculated the associ-
ation of each haplotype block with LDL-C values by using the
haplo.stats package (Mayo Foundation for Medical Education
and Research). The results are presented as P values based on
the global statistic for the association of haplotype blocks with
LDL-C level. Testing was performed at the nominal signiﬁ-
cance threshold of 0.05.
Results
Nonsynonymous Sequence Variations in PCSK9
To identify sequence variations in PCSK9 associated
with hyper- or hypocholesterolemia in the general pop-
ulation, we sequenced the exons and ﬂanking intronic
regions of PCSK9 in four groups of individuals (black
men, black women, white men, and white women) from
the DHS sample who had either very low (!5th percen-
tile) or very high (195th percentile) plasma levels of
LDL-C. The DHS sample is a multiethnic (52% non-
Hispanic black, 29% non-Hispanic white, 17% His-
panic, and 2% other ethnicities) probability-based pop-
ulation sample of Dallas County for which ethnicity was
self-assigned (Victor et al. 2004). The low- and high-
LDL groups each included 39 (of 770) black men, 50
(of 1,051) black women, 25 (of 499) white men, and
27 (of 544) white women. A total of 6.1% of the sam-
ple population were taking cholesterol-lowering agents
(6.0% of blacks and 7.6% of whites). Since the mean
reduction in plasma LDL-C level in individuals taking
a statin is ∼25% (Sacks and Katan 2002), we estimated
the untreated plasma LDL-C level of those individuals
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Figure 3 Plasma LDL-C levels in blacks in the DHS (A) and
Cook County (C) samples. The mean (solid lines) and SD (dashed
lines) of plasma LDL-C levels adjusted for age and sex are shown.
Horizontal bars, Mean plasma LDL-C levels for each sequence variant
(omitted if ). Signiﬁcantly lower or higher plasma LDL-C levelsn ! 6
are indicated by green- or yellow-shaded bars, respectively. B, Mean
( SEM) of the plasma LDL-C level at the A443T variation in the
DHS blacks (left set of bars) and Cook County subjects (right set of
bars). The number of subjects in each group is given above the bars.
* , ** ; by pairwise two-sided t tests withHolm correctionP ! .05 P ! .01
for multiple comparisons.
taking a cholesterol-lowering agent by adding 33% to
their levels measured while taking treatment. A total of
35 subjects who were taking lipid-lowering agents were
included among the 141 individuals in the high-LDL
group (26 of 89 blacks and 9 of 52 whites).
DNA sequencing revealed 19 nonsynonymous se-
quence variations in PCSK9, including 17 missense mu-
tations and 2 nonsense mutations (ﬁg. 1). Six mutations
(four missense mutations and two nonsense) were iden-
tiﬁed in only the low-LDL subjects, and six were found
in only the high-LDL subjects. Thus, the overall prev-
alence of PCSK9 mutations was similar in the groups
with low and high LDL-C. We have shown elsewhere
that both of the nonsense mutations in PCSK9 are as-
sociated with low plasma levels of LDL-C (Cohen et al.
2005). To determine whether any of the missense mu-
tations identiﬁed were associated with plasma LDL-C
levels, each mutation was assayed in the entire DHS
sample with ﬂuorogenic 5′-nucleotidase (TaqMan) as-
says (table 1). In the DHS sample, all 19 nonsynonymous
mutations were present in blacks, whereas only 9 were
found in whites. Accordingly, the two populations were
analyzed separately by using one-way analysis of vari-
ance. Only one of the nonsynonymous sequence varia-
tions, R46L, was signiﬁcantly associated with plasma
LDL-C levels in the white subjects ( ) (ﬁg. 2A).4P ! 10
In the white men and white women, heterozygotes for
the minor allele (L46) had signiﬁcantly lower plasma
levels of LDL-C (ﬁg. 2B).
Among blacks, three missense mutations (L253F,
A443T, and H553R) were associated with plasma LDL-
C levels (ﬁg. 3A). The L253F and A443Tmutations were
associated with low LDL-C levels: heterozygotes for the
F253 allele had a 30% reduction in mean plasma LDL-
C levels (L/L 104.6 mg/dl; L/F 73.2 mg/dl), whereas ho-
mozygotes for the T443 variant had a 29% reduction
in plasma levels of LDL-C (ﬁg. 3A and 3B). The H553R
mutation was associated with increased plasma levels of
LDL-C ( ). All three mutations were either veryP ! .05
rare (A443T) or absent (L235F and H553R) among
whites. The R46L sequence variation, which was sig-
niﬁcantly associated with LDL-C levels in whites, was
much less common in blacks (minor-allele frequency
0.28%), and the decrease in LDL-C levels among het-
erozygotes did not achieve statistical signiﬁcance in this
population (mean plasma levels: R/R 104.5 mg/dl; R/L
93.8 mg/dl; ).Pp .35
To test the reproducibility of these ﬁndings, we as-
sayed the nonsynonymous PCSK9 sequence variations
that were signiﬁcantly associated with plasma LDL-C
levels and all nonsynonymous sequence variants that
were found only in the low-LDL group or only in the
high-LDL group in 850 blacks from Cook County (ﬁg.
3C). The mean plasma LDL-C level of the Cook County
sample was slightly lower than that of the DHS sample,
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Table 2
Demographic Characteristics of the Blacks in the DHS and Cook County Samples
CHARACTERISTIC
ALL BLACKS BLACK MEN BLACK WOMEN
DHS Cook County DHS Cook County DHS Cook County
Total no. of subjects 1,822 850 771 523 1,051 315
No. (%) of men 771 (42) 523 (62)a 771 (100) 523 (100) NA NA
Age (years) 45  10 42  7a 45.1  10 43  7a 45  10 41  7a
BMI 32.0  8.1 26.6  7.3a 29.6  7.1 25.2  5.9a 33.7  8.8 28.8  9.1a
Cholesterol (mg/dl) 177  39 172  38b 177  39 170  37b 178  39 175  39
Triglyceride (mg/dl)c 88 (59) 85 (62) 92 (72) 85 (64) 83 (50) 82 (59)
LDL-C (mg/dl) 104  36 99  37a 104  37 96.8  36a 105  35 103  39
HDL-C (mg/dl) 52  15 52  15 50  16 52  16d 54  15 52  15d
VLDL-C (mg/dl)c 17 (12) 17 (12) 18 (14) 17 (13) 17 (10) 16 (12)
NOTE.—Data are mean (SD) unless indicated otherwise. All lipoprotein levels and BMIs were adjusted for age
(and sex, where appropriate) by linear regression. Percentages were compared by two-sided Fisher’s exact test, and
means were compared by two-sided Welch t test. HDL-Cp high-density lipoprotein cholesterol; NAp not applicable.
a .P ! .001
b .P ! .01
c Data are medians (interquartile range).
d .P ! .05
perhaps reﬂecting the younger ages and lower BMIs (cal-
culated as weight in kilograms divided by the square of
height in meters) of the Cook County participants (table
2). Our power to detect associations was lower in the
Cook County sample than in the DHS blacks because
of the smaller sample size. Nevertheless, the L235F and
A443T sequence variations were both signiﬁcantly as-
sociated with low LDL-C levels in the Cook County
sample. The H553R variation was not associated with
LDL-C levels in this sample. This could reﬂect limited
statistical power to detect modest effects of rare alleles,
but the ﬁnding that the mean plasma LDL-C level was
slightly lower, rather than higher, in the H553R hetero-
zygotes than in the H553 homozygotes suggests that this
is unlikely.
Mutations in PCSK9 Are Not Associated with
Increased HTGC
Mutations that cause low plasma levels of LDL-C due
to reduced hepatic VLDL secretion are associated with
accumulation of triglyceride in the liver (Schonfeld et
al. 2003). If mutations in PCSK9 cause a reduction in
plasma LDL-C levels by reducing the rate of VLDL se-
cretion, it would be anticipated that subjects with hy-
pocholesterolemia due to mutations in PCSK9 would
have hepatic steatosis. We examined the relationship be-
tween the LDL-lowering variants in PCSK9 (R46L in
whites and Y142X [Cohen et al. 2005], L253F, A443T,
and C679X [Cohen et al. 2005] in blacks) and the
HTGC as determined using proton magnetic resonance
spectroscopy (Browning et al. 2004; Szczepaniak et al.
2004) in 747 whites and 1,090 blacks in the DHS
sample. The HTGC was not measured in the one DHS
white individual who had a PCSK9 nonsense mutation.
The “LDL-lowering variants” group includes the DHS
whites with R46L ( ) and the DHS blacks with anp 26
nonsense mutation ( ), L253F ( ), or A443Tnp 20 np 3
(heterozygotes and homozygotes, ).np 185
In the whites, the median HTGC did not differ sig-
niﬁcantly between the subjects with the LDL-lowering
variant R46L, and the subjects with no LDL-lowering
variant (4.5% vs. 3.5%; , by two-sidedWilcoxonPp .4
rank sum test) (ﬁg. 4). In the blacks, the median HTGC
did not differ signiﬁcantly between the subjects with an
LDL-lowering nonsense mutation and the subjects with
no LDL-lowering variant (2.0% vs. 3.2%; ) orPp .2
between the subjects with an LDL-lowering missense
variant and the subjects with no LDL-lowering variant
(3.2% in both groups). Essentially identical results were
obtained when individuals with diabetes or impaired
glucose tolerance were excluded (data not shown).
Evolutionary Conservation of Nonsynonymous
Sequence Variations in PCSK9
To assess the relationship between the evolutionary
conservation and functional effects of the nonsynony-
mous sequence variations identiﬁed, we aligned the hu-
man PCSK9 amino acid sequence with the orthologous
sequences from other mammals, birds, amphibians, and
ﬁsh (ﬁg. 5). The three PCSK9 mutations associated with
Mendelian hypercholesterolemia were at highly con-
served amino acid residues. Of the 17 missense sequence
variations identiﬁed in the present study, 12 changed
amino acid residues that are completely conserved in
primates and mice, and 8 were at amino acid residues
conserved from humans to frogs. Only one (L253F) of
these eight was associated with plasma LDL-C levels.
The other two mutations associated with plasma LDL-
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Figure 4 Median HTGC in whites and blacks with nonsynon-
ymous sequence variations in PCSK9 associated with low plasma levels
of LDL-C. HTGC was measured using proton magnetic resonance
spectroscopy as described elsewhere (Browning et al. 2004). The me-
dian HTGC of the whites with or without an LDL-lowering variation
(R46L) and the median HTGC of the blacks with or without either a
nonsense mutation (Y142X or C679X) or a missense sequence variant
(L253F or A443T) associated with a lower level of LDL-C were com-
pared (by two-sided Wilcoxon rank sum test). The number of subjects
in each group is given above the bars. The threshold for hepatic stea-
tosis, deﬁned as HTGC 15.5% (Browning et al. 2004), is indicated
(arrow).
C levels (R46L and A443T) were at amino acid residues
conserved only among primates. One sequence variant
(F515L) at a highly conserved residue was identiﬁed in
only a single hypercholesterolemic black subject, so its
functional signiﬁcance could not be determined. These
data indicate that the extent of evolutionary sequence
conservation did not reliably predict the impact of se-
quence variation on protein function.
We also examined the utility of three computer-based
algorithms for predicting the functional effects of the
nonsynonymous variations: PolyPhen (polymorphism
phenotyping) (Sunyaev et al. 2001), SIFT (sorting in-
tolerant from tolerant) (Ng and Henikoff 2003), and
PANTHER (protein analysis through evolutionary re-
lationships) (Thomas et al. 2003). SIFT and PANTHER
use sequence similarity to predict whether an amino acid
substitution affects protein function, whereas PolyPhen
uses sequence similarity as well as structural information
for its predictions. Each of these algorithms predicted
that approximately one-half of the PCSK9 missense se-
quence variations detected in the DHS sample have del-
eterious effects on PCSK9 function (41%, 57%, and
53% for SIFT, PANTHER, and PolyPhen, respectively)
(ﬁg. 5). SIFT failed to correctly identify any of the three
missense sequence variations associated with plasma lev-
els of LDL-C and also failed to predict two of the mu-
tations in PCSK9 that cause dominant hypercholester-
olemia (Abifadel et al. 2003; Leren 2004; Timms et al.
2004). PANTHER predicted two of the three functional
sequence variations as well as two of the three disease-
causing mutations; however, this program also incor-
rectly predicted that six of the missense substitutions
would be functional. Finally, PolyPhen correctly pre-
dicted just one of the three missense polymorphisms and
mutations that were associated with plasma levels of
LDL-C.
Noncoding Sequence Variations in PCSK9
To investigate more comprehensively the contribu-
tions of synonymous and noncoding sequence variations
in PCSK9 to interindividual differences in plasma LDL-
C level in the general population, we genotyped the black
and white subjects in the DHS sample for 94 SNPs that
span the entire PCSK9 locus, extending ∼10 kb upstream
and downstream of the 5′ and 3′ UTRs of PCSK9. One
of these SNPs is a synonymous substitution in exon 9
(V460V); the remainder are located outside the PCSK9
coding sequence. For each ethnic group, we analyzed all
SNPs with a minor-allele frequency of at least 1% (75
SNPs in the whites and 89 SNPs in the blacks).
Analysis of variance indicated that one SNP was sig-
niﬁcantly associated with plasma levels of LDL-C in
whites, and seven were signiﬁcantly associated with
plasma levels of LDL-C in blacks (ﬁg. 6). Six other SNPs
met the nominal signiﬁcance threshold of 0.05 but were
excluded from further consideration because the mean
plasma LDL-C levels of heterozygotes were higher or
lower than the mean plasma LDL-C levels of homozy-
gotes for both the common and rare alleles.
The single noncoding SNP that was associated with
LDL-C levels in whites was rare (minor-allele frequency
1.7%) and was not associated with LDL-C levels in
blacks (data not shown). Therefore, this allele was not
evaluated further. For each of the seven noncoding SNPs
that were signiﬁcantly associated with plasma LDL-C
levels in blacks, we tested for replication in the Cook
County subjects (table 3). The genotype frequencies of
all seven SNPs were similar in the two populations.
Three of the seven noncoding SNPs were also signiﬁ-
cantly associated with plasma LDL-C levels in the Cook
County subjects (SNPs 3, 6, and 7 in ﬁg. 6B). SNP 7 is
located downstream of the PCSK9 3′ UTR, in the last
intron of an adjacent gene, USP24, which is transcribed
in the opposite direction from PCSK9 and encodes a
ubiquitin carboxyl-terminal hydrolase. No disease-
associated mutations in USP24 have been reported to
date. SNP 7 is in linkage disequilibrium with the SNP
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Figure 5 Evolutionary sequence conservation and predicted
functional effects of missense sequence variations in PCSK9. Conser-
vation for each variation found in the low-LDL subjects only (green),
the high-LDL subjects only (yellow), or both groups (gray) of the DHS
sample and in patients with autosomal dominant hypercholesterolemia
(red) (Abifadel et al. 2003; Leren 2004; Timms et al. 2004) is high-
lighted. An asterisk (*) indicates a SNP signiﬁcantly associated with
plasma LDL-C level. Sequences are shown for Homo sapiens, Pan
troglodytes, Rhesus macaque, Mus musculus, Rattus norvegicus, Gal-
lus gallus, Xenopus tropicalis, Xenopus laevis, Danio rerio, Fugu rub-
ripes, Tetraodon nigroviridis, andOryzias latipes. The predicted effect
of each amino acid sequence variation on protein function is indicated
(right columns). ASIFT v.2:  p tolerated;  p deleterious (low-
conﬁdence prediction);  p deleterious. BPANTHER v.5.0:  p
unlikely functional effect;  p possible deleterious functional effect;
 p high probability of deleterious functional effect; NA p not
modeled by the PANTHER hidden Markov model (family sequence
alignment absent or poor). CPolyPhen:  p benign;  p possibly
damaging;  p probably damaging (Sunyaev et al. 2001; Ng and
Henikoff 2003; Thomas et al. 2003).
corresponding to A443T ( ; ). The ef-2 ′r p 0.5 D p 0.85
fects of these noncoding SNPs on plasma LDL-C level
were much smaller than those of the coding sequence
variations (2.6% increase to 4.1% decrease) (table 4).
None of these three noncoding SNPs were located in a
region of sequence conservation between human and
mouse PCSK9, as determined by VISTA alignment
(Couronne et al. 2003).
Haplotype Blocks in PCSK9
Next, we queried whether combinations of closely
linked sequence variations in PCSK9 contributed to
plasma levels of LDL-C. We used all SNPs with a minor-
allele frequency of at least 1% to construct haplotype
blocks across the PCSK9 locus and then calculated a
global P value for association of each haplotype block
with plasma LDL-C level (ﬁg. 6). Of the nine estimated
haplotype blocks in the DHS whites, one was signiﬁ-
cantly associated with plasma LDL-C level (ﬁg. 6A). Nei-
ther of the two sequence variations (R46L and SNP
1033079) that were signiﬁcantly associated with plasma
LDL-C level in the DHS whites is located within this
518-bp haplotype block. Of the 15 estimated haplotype
blocks in the DHS blacks, 5 were signiﬁcantly associated
with plasma LDL-C levels (ﬁg. 6B). Two of the PCSK9
sequence variations that were signiﬁcantly associated
with plasma LDL-C level in both the DHS blacks and
the Cook County subjects (SNPs 6 and 7 in ﬁg. 6B) were
located within one of the ﬁve haplotype blocks associ-
ated with plasma levels of LDL-C.
To determine whether the observed associations be-
tween the haplotype blocks and plasma LDL-C levels
were driven by the SNPs that were individually associ-
ated with plasma LDL-C levels (see above), we excluded
these SNPs from the analysis and retested for association
of the haplotype blocks with plasma LDL-C level. In the
whites, the exclusion of the signiﬁcant SNPs did not
affect the association of block 6 with plasma LDL-C
level (ﬁg. 6A). In the blacks, however, only one of the
ﬁve haplotype blocks—block 10, which contained just
two SNPs (1033044 and 1033045), located 58 bp
apart—remained associated (ﬁg. 6B). This block did not
overlap with block 6 in the whites, and neither of these
two haplotype blocks was located in a region of sequence
conservation between human and mouse PCSK9 (Bray
et al. 2003; Couronne et al. 2003).
Discussion
The major ﬁnding of this study is that a spectrum of
alleles of PCSK9 are associated with a range of effects
on plasma levels of LDL-C. We identiﬁed three missense
variations and two noncoding sequence variants that
were signiﬁcantly and reproducibly associated with
lower plasma levels of LDL-C. These sequence variants
most likely lower LDL-C levels by impairing PCSK9 ac-
tivity, since nonsense mutations in PCSK9 are associated
with low plasma levels of LDL-C (Cohen et al. 2005).
In addition, we identiﬁed a single noncoding SNP as-
sociated reproducibly with a modest (∼3%) but statis-
tically signiﬁcant increase in LDL-C. The effects of the
PCSK9 variants on lipoprotein metabolism were ex-
tremely speciﬁc; individuals with LDL-lowering PCSK9
alleles did not have signiﬁcant alterations in plasma lev-
els of other lipids or lipoproteins (table 5) and did not
have increased HTGC. These ﬁndings are consistent
with the sequence variants associated with low plasma
levels of LDL-C impairing PCSK9 activity and lowering
LDL-C levels by accelerating LDL clearance rather than
by reducing the secretion of VLDL from the liver.
The spectrum of PCSK9 alleles associated with LDL-C
spanned a wide range of allele frequencies (0.2%–34%)
and magnitude of phenotypic effects (∼3% increase to
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Figure 6 Haplotype block structure across PCSK9 and P values for signiﬁcance of association of common SNPs with plasma LDL-C level
in whites (A) and blacks (B) in the DHS sample. SNPs and haplotype blocks are plotted along the X-axis according to genomic position. The
P value for each SNP is plotted above or below the midline according to whether the mean plasma LDL-C level of the heterozygous genotype
is higher (above midline) or lower (below midline) than the mean plasma LDL-C level of the homozygous common genotype. Coding SNPs
signiﬁcantly associated with plasma LDL-C level are indicated (arrows), and the corresponding amino acid sequence variations are given. Arabic
numerals indicate the noncoding SNPs signiﬁcantly associated with plasma LDL-C level in whites (1) or blacks (1–7). SNPs that were also
signiﬁcant in the Cook County sample are circled. The extents of haplotype blocks are indicated (shaded rectangles). Haplotype blocks signiﬁcantly
associated with plasma LDL-C level are shaded in pink. P values for haplotype blocks are based on the global statistic. Asterisks (*) indicate
haplotype blocks that were signiﬁcantly associated with plasma LDL-C level after exclusion of all SNPs that were individually associated with
plasma LDL-C level. Dashed lines, . The genomic structure of PCSK9 is shown schematically above the plots. Genomic positions arePp .05
based on National Center for Biotechnology Information (NCBI) build 34 of the human genome.
49% reduction in LDL-C) (table 4). Thus, unlike the
other genes associated with Mendelian forms of hyper-
cholesterolemia (LDLR, APOB, ARH, ABCG5, and
ABCG8), common sequence variants in PCSK9 also
contribute signiﬁcantly to interindividual variation in
plasma levels of LDL-C. Taken together, our results sug-
gest that the genetic architecture of plasma LDL-C levels
is complex, with multiple common and rare alleles with
small and large phenotypic effects contributing signiﬁ-
cantly to plasma LDL-C levels in the population.
Five of the six PCSK9 alleles that were reproducibly
associated with LDL-C in this study caused a reduction
in plasma LDL-C levels. Only a single missensemutation
that might cause autosomal dominant hypercholester-
olemia was identiﬁed in this study; one black with an
LDL-C of 184 mg/dl had a phenylalaninerleucine sub-
stitution at residue 515. We are currently examining the
family of this individual to determine whether the se-
quence variation cosegregates with hypercholesterol-
emia. None of the missense mutations in PCSK9 that
have been associated with autosomal dominant hyper-
cholesterolemia (S127R, F216L, and D374Y) (Abifadel
et al. 2003; Leren 2004; Timms et al. 2004) were iden-
tiﬁed in the DHS sample. One common noncoding se-
quence variant was associated with a small but repro-
ducible increase in plasma LDL-C levels. Thus, most
PCSK9 alleles that contribute to interindividual varia-
tion in plasma LDL-C levels in whites and blacks act by
reducing PCSK9 activity.
Comprehensive evaluation of both coding and non-
coding variation in PCSK9 required statistical analysis
of 1100 sequence variants (17 nonsynonymous, 1 syn-
onymous, and 93 noncoding). Nonetheless, the genetic
associations reported here are unlikely to be a fortuitous
consequence of multiple testing. Of the 106 sequence
variants tested in blacks in the DHS sample, 5 would be
expected to be signiﬁcantly associated with LDL-C at a
nominal signiﬁcance threshold of 0.05 simply by chance,
and none of these would be expected to achieve this
signiﬁcance threshold in a replicate analysis of an in-
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Table 3
Association between Sequence Variations in PCSK9 and Plasma
LDL-C Levels in Blacks
Subjects and Variants
DHS Blacksa
( )np 1,711
Cook County Sampleb
( )np 780
Low-LDL subjects only:
E57K .60 .637
Y142X .00017 NA
L253F .021 .00010
H391N .156 NA
Q554E .103 NA
C679X 4.3# 108 1.3# 105
High-LDL subjects only:
R237W NA 
H417Q .106 NA
R469W .47 .158
E482G NA NA
F515L NA 
H553R .0476 .59
Low- and high-LDL subjects:
R46L .345 NA
A53V .298 ND
N425S .845 ND
A443T .0014 .0027
I474V .125 ND
Q619P .387 ND
E670G .244 ND
Decreased LDL-C:
54879790_4427356c .042 .45
54882467_4342503c .000431 .93
54888986_1033060c .00134 .0015
54907116_1033098c .000462 .027
Increased LDL-C:
54884133_4319928c .037 .13
54887262_1033043c .011 .057
54891027_4814882c .016 .014
NOTE.—NAp not applicable because heterozygous or homozygous
rare genotype count was !6; ND p not genotyped in Cook County
subjects;  p monoallelic. Bold italics indicate .P ! .05
a P values calculated by one-way analysis of variance.
b P values calculated by one-sided t test.
c Noncoding SNPs. Sequence variations are denoted by the chro-
mosomal position according to NCBI build 34 of the human genome,
followed by the Perlegen reference number.
dependent sample. In contrast, 10 of the 106 sequence
variants assayed in blacks in the DHS sample achieved
the nominal signiﬁcance threshold of 0.05, and 5 of these
also achieved a P value !.05 in the Cook County sample.
For all ﬁve sequence variants, the direction of effect was
the same in both populations.
We failed to conﬁrm any of the previously reported
associations between sequence variations in PCSK9 and
differences in plasma levels of LDL-C (Shioji et al. 2004;
Chen et al. 2005). Two common SNPs, IVS1161CrT
and I474V, associated with decreased plasma levels of
LDL-C in a Japanense sample were not associated with
reduced plasma levels of LDL-C in the DHS sample
(Shioji et al. 2004). Nor was any association found be-
tween plasma levels of LDL-C and a common E670G
substitution whose corresponding allele was part of a
haplotype associated with increased plasma levels of
LDL-C in hypercholesterolemic subjects from Houston
(10% nonwhite) (Chen et al. 2005).
The molecular mechanism by which sequence varia-
tions in PCSK9 affect plasma LDL-C levels remains con-
troversial. Studies in genetically manipulated mice sug-
gest that PCSK9 affects plasma LDL-C levels by altering
hepatic LDLR levels: overexpression of wild-type PCSK9
in mouse liver by adenovirus-mediated transgenesis is
associated with a marked reduction in hepatic LDLRs
and a corresponding increase in plasma cholesterol levels
(Dubuc et al. 2004; Park et al. 2004), whereas deletion
of PCSK9 results in an increase in LDLR protein levels
(Rashid et al. 2005). It has also been proposed that mu-
tations in PCSK9 affect plasma LDL-C levels by altering
the rate of secretion of VLDL from the liver (Benjannet
et al. 2004; Ouguerram et al. 2004; Sun et al. 2005). If
the hypercholesterolemia associated with selected mis-
sense mutations in PCSK9 is due to increased VLDL
synthesis, then the hypocholesterolemia associated with
the nonsense mutations is predicted to result in decreased
VLDL secretion, as occurs in two Mendelian forms of
hypocholesterolemia: hypobetalipoproteinemia and
abetalipoproteinemia. Both of these diseases are char-
acterized by an accumulation of triglyceride in the liver
due to the reduction in VLDL secretion (Schonfeld et al.
2003). In the present study, we did not detect any sig-
niﬁcant difference in the median HTGC or in the prev-
alence of hepatic steatosis between the subjects with
and the subjects without an LDL-lowering mutation in
PCSK9, in either ethnic group. This ﬁnding suggests that
impaired VLDL secretion is not the major mechanism
by which loss-of-function mutations in PCSK9 decrease
plasma LDL-C levels.
The mechanisms by which the sequence variations
identiﬁed in this study affect PCSK9 activity are not
known. One of the missense mutations associated with
plasma levels of LDL-C (L235F) affected a residue that
was completely conserved among all species examined,
from humans to ﬁsh. Surprisingly, the residues that were
altered by the other two functional missense mutations
(R46L and A443T) were poorly conserved. Codon 46
speciﬁes a hydrophobic amino acid in most species (pro-
line in rodents, alanine in frogs, and isoleucine in ze-
braﬁsh). Similarly, the residue affected by the A443T
substitution is threonine in rodents and glycine in birds
and frogs. Since no biochemical assay for PCSK9 is avail-
able, we cannot determine whether these substitutions
directly affect protein activity or whether they affect the
expression level of the protein. It is also possible that
these sequence variants do not directly affect PCSK9
activity but are in linkage disequilibriumwith other non-
coding polymorphisms that affect PCSK9 expression.
The identiﬁcation of a wide spectrum of amino acid
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Table 4
Magnitude of Effect of the PCSK9 Sequence Variations Reproducibly
Associated with Plasma LDL-C Levels in the DHS Sample
Effect,
Sequence Variation,
and Genotype
No. of
Individuals
Mean  SD
LDL-C
(mg/dl)
Difference in
Mean LDL-Ca
(mg/dl)
Decreased LDL-C:
54875565_R46Lb:
G/G 928 110.1  33.31
G/T 32 86.61  30.52 23.5 (21.3)
54882140_Y142Xc:
C/C 1,691 104.7  35.73
C/G 7 53.84  32.89 50.9 (48.6)
54888340_L253Fc:
C/C 1,692 104.6  35.92
C/T 7 73.17  41.28 31.4 (30.0)
54893773_A443Tc:
G/G 1,378 105.3  36.15
G/A 292 101.6  33.92 3.7 (3.5)
A/A 15 74.46  18.48 30.8 (29.2)
54899133_C679Xc:
C/C 1,672 105  35.82
C/A 26 66.27  20.84 38.7 (36.9)
54888986_1033060c:
A/A 1,021 106.7  36.78
A/T 535 102.3  34.69 4.4 (4.1)
T/T 71 92.8  31.14 13.9 (13.0)
54907116_1033098c:
G/G 1,218 105.7  36.67
G/A 383 102.4  33.92 3.3 (3.1)
A/A 21 76.46  25.68 29.2 (27.6)
Increased LDL-C:
54891027_4814882c:
G/G 704 102.4  34.55
G/A 750 105.1  36.61 2.7 (2.6)
A/A 173 111  38.60 8.6 (8.4)
NOTE.—Sequence variations are denoted by the chromosomal position
according to NCBI build 34 of the human genome, followed by either the
amino acid change or the Perlegen reference number.
a Difference in mean plasma LDL-C level (and percentage) relative to
homozygous common genotype.
b In whites.
c In blacks.
sequence variations in PCSK9, coupled with the ability
to test for association of these variations with a phe-
notype directly related to PCSK9 function in a large
population sample, provided an opportunity to assess
the utility of computer-based prediction algorithms.
None of the three algorithms predicted any of the mis-
sense variations signiﬁcantly associated with plasma
LDL-C level to have a deleterious effect with high prob-
ability; moreover, each of the three functional sequence
variations was predicted by at least one of the algorithms
to be benign, and A443T was predicted by all three
algorithms to be benign. This latter prediction by all
three programs is likely a result of the presence of T443
in rodent PCSK9. This might be explained by differences
in the effect of this mutation between humans and ro-
dents or by the co-occurrence of one or more compen-
sating mutations (Kondrashov et al. 2002). In addition,
64% of the sequence variations that were not associated
with plasma LDL-C levels were predicted by at least one
of the algorithms to be deleterious. Thus, in silico pre-
diction methods were poor predictors of functional var-
iation in PCSK9. It is possible that the number of or-
thologous sequences used in this analysis did not provide
adequate power to assess the spectrum of amino acids
permitted at each position in the protein. In this case,
the performance of these algorithms could potentially
be improved by greatly increasing the number of ref-
erence sequences included in the alignment. Alterna-
tively, the poor performance of the algorithms may re-
ﬂect intrinsic limitations of in silico prediction. This
problem may be particularly pertinent for sequence var-
iations that have more-subtle effects on protein function.
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Table 5
Demographic Characteristics of DHS Blacks With and Without
LDL-Lowering Nonsynonymous Variations in PCSK9
CHARACTERISTIC
LDL-LOWERING
NONSYNONYMOUS SEQUENCE
VARIATIONSa
Blacks Without Blacks With
Total no. of subjects 1,423 354
No. (%) of men 601 (42) 150 (42)
Age (years) 44.9  10.3 44.1  10.1
BMI 32  8.12 31.8  7.73
No. (%) of diabetics 286 (20) 70 (20)
Cholesterol (mg/dl) 179  39.3 172  36.1b
Triglyceride (mg/dl)c 88 (58) 91 (60)
LDL-C (mg/dl) 106  35.9 97.3  34.5d
HDL-C (mg/dl) 52  14.9 53.4  16.3
VLDL-C (mg/dl)c 17 (11) 18 (12)
HTGC (%)c 3.2 (3.2) 3.2 (3.0)
NOTE.—Values were compared between subjects without and sub-
jects with a nonsynonymous sequence variation in PCSK9 that was
signiﬁcantly associated with decreased plasma LDL-C level in the DHS
blacks (Y142X, L253F, A443T, and C679X). All lipoprotein levels and
BMIs were adjusted for age and sex by linear regression. Percentages
were compared by two-sided Fisher’s exact test, means were compared
by two-sided Welch t test, and medians were compared by two-sided
Wilcoxon rank sum test.
a Data are mean  SD unless otherwise indicated.
b .P ! .01
c Data are median (interquartile range).
d .P ! .001
The results of this study have important implications
for the genetic architecture of quantitative traits and for
strategies to identify functional sequence variants. First,
our data provide further support for the importance
of rare sequence variants with large phenotypic effects.
Among blacks, 3% of the population carries a PCSK9
allele that is associated with a mean reduction in plasma
LDL-C levels of ∼35%. The LDL-lowering effect of these
rare PCSK9 alleles is comparable to the effects achieved
by 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors (statins). Thus, carriers of these mutations
should have substantial protection from coronary heart
disease. Second, our data also support a role for common
PCSK9 variants (both coding and noncoding) in deter-
mining plasma levels of LDL-C. The effects of these var-
iants were much smaller than the effects associated with
the rare variants; the plasma LDL-C levels among in-
dividuals with one of the common LDL-loweringPCSK9
alleles differed by !5% from the levels of those without
the allele. Finally, although 1100 sequence variants in
PCSK9 were analyzed in this study, only a small number
were systematically associated with plasma LDL-C lev-
els. For each of the functional sequence variants iden-
tiﬁed, several closely linked SNPs did not show any sig-
niﬁcant association with plasma LDL-C levels (ﬁg. 6).
Haplotype blocks constructed using multiple highly in-
formative SNPs also failed to reveal association with
plasma LDL-C levels unless the putatively functional
SNP was included in the analysis. These results suggest
that very dense SNP analysis may be required for genetic
association studies and that analysis of common se-
quence variants is unlikely to reveal the effects of rare
alleles in the population.
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.nih.gov/Omim/ (for LDLR, autosomal dominant hypercholesterol-
emia, and autosomal recessive hypercholesterolemia)
PANTHER, https://panther.appliedbiosystems.com/
PolyPhen, http://www.bork.embl-heidelberg.de/PolyPhen/
Sorting Intolerant From Tolerant (SIFT), http://blocks.fhcrc.org/sift/
SIFT.html
The R Project for Statistical Computing, http://www.r-project.org/
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